The European Medicines Agency (EMA) has granted PRiority Medicines (PRIME) designation to Singapore-based Tessa Therapeutics' lead autologous CD30 CAR-T therapy intended for the treatment of relapsed or refractory classical Hodgkin Lymphoma, it was reported on Monday.
PRIME is intended to optimise development plans and accelerate assessment of medicines that showcase major therapeutic advantage over present treatments, or otherwise benefit patients without treatment options. The EMA also provides improved support to medicine developers including early interaction and dialogue, and a pathway for accelerated assessment by the agency.
The PRIME designation was offered to Tessa based on the clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center. These studies indicated complete disappearance of tumour in around 60% of patients at the highest dose level, with none of the serious toxicities that can be linked to several other CAR-T therapies.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT